Manipal Health Enterprises reported a 25.4% jump in FY26 revenue to Rs 10,335.75 crore, though profit moderated to Rs 916.59 crore. The hospital network, which successfully listed in August 2026, continues to focus on high-acuity medical specialties and aggressive expansion through acquisitions like Sahyadri Hospitals.
Manipal Health Enterprises FY26 Financial Results
Consolidated revenue stood at Rs 10,335.75 crore with a profit after tax of Rs 916.59 crore.
Reader Takeaway: Robust 25% revenue growth driven by network expansion, balanced against initial integration costs of new acquisitions.
What just happened
Manipal Health Enterprises has released its fiscal performance for the year ending March 31, 2026. The company reported a significant 25.4% increase in revenue, climbing from Rs 8,242.26 crore to Rs 10,335.75 crore. Consolidated EBITDA reached Rs 2,644 crore, representing a margin of 25.6%. Profit after tax for the period settled at Rs 916.59 crore.
Why this matters
The company, which successfully completed its IPO in August 2026, is currently scaling its footprint. Its portfolio of 49 hospitals and 13,037 beds served over 76 lakh patients this year. The firm's focus on high-end medical care, specifically Cardiac, Oncology, Neuro, Gastro, Orthopaedics, and Renal specialties, accounted for nearly 65% of inpatient revenue, signaling strong specialization capabilities.
The backstory
The fiscal year saw a major inorganic growth move with the acquisition of Sahyadri Hospitals in October 2025, strengthening the company's presence in Maharashtra. This expansion is central to its post-listing strategy to capture a larger share of the tertiary and quaternary care market.
What changes now
Shareholders will vote on several key items at the upcoming 16th AGM on September 29, 2026. These include the appointment of Price Waterhouse Chartered Accountants LLP as statutory auditors for a five-year term and amendments to the Articles of Association regarding nomination rights for major stakeholders including the Temasek Group and MGHS Group.
Risks to watch
Investors should monitor the integration of the Sahyadri hospital chain and how management maintains EBITDA margins while scaling operations. Changes to board nomination rights and shareholding thresholds for large investors remain points for careful governance scrutiny.
What to track next
Watch for the successful implementation of the 'ESOP 2024 Plan' expansion and any further updates on the upside-sharing arrangement with TPG SG Magazine.